83 signals · alpha_vantage, bluesky, News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Elevated risk signals — operational or reputational pressure patterns observed.
Sanofi exhibits mixed signals with program termination risks offset by analyst upgrades and a major partnership deal.
Patterns indicate Sanofi is navigating a high-risk environment, as evidenced by a discontinued Phase 1 trial and program termination, which may weigh on near-term sentiment. However, signals suggest mitigating factors, including a significant financial partnership and upward price target revisions, though the overall stress and risk levels remain elevated. Confidence in these observations is high (80.0/100) but should account for limited review coverage (83 total).
🔴 $NRIX — Clinical Milestone Sanofi Discontinues SAR448272 Phase 1 Trial and Terminates Program Sanofi notified Nurix it is discontinuing the Phase 1 first-in-human trial of oral STAT6 degrader SAR448272 and terminating the program. Nurix no longer expects fut… https://biostock.app/symbols/NRIX
🔴 $NRIX — Clinical Milestone Sanofi Discontinues SAR448272 Phase 1 Trial and Terminates Program Sanofi notified Nurix it is discontinuing the Phase 1 first-in-human trial of oral STAT6 degrader SAR448272 and terminating the program.
Sanofi price target raised to EUR 80 from EUR 75 at RBC Capital TipRanks
Multinational pharmaceutical company.
Based on 83 signals across 3 sources · snapshot 4 Nov 2026
Strong: enough recent evidence to trust this score.
Overall community sentiment for Sanofi is mixed based on public signals as of 4 Nov 2026.
Based on 83 signals across 3 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
Pharmaceuticals industry average
What this means
Moderate internal stress paired with elevated risk signals — conditions bear watching.
AI-generated from public signals — may be incomplete. Based on 3 recent signals.
This summary is generated from publicly available review and signal data. It is intended as an indicative overview only and should not be used as the sole basis for employment, investment, or business decisions. Signal volume and source diversity may limit representativeness.
AI summaries are generated from public signals and may not reflect the full picture.
💰 Sanofi's $1 Billion Deal Regeneron secured a $1 billion upfront payment from Sanofi. This deal includes up to $7 billion for next-gen antibodies. The company's revenue rose 36% to $5.1 billion in Q3. https://finance.yahoo.com/markets/stocks/articles/regeneron-regn-stock-trades-why-093929499.htm
💰 Sanofi's $1 Billion Deal Regeneron secured a $1 billion upfront payment from Sanofi.